Supernus Pharmaceuticals, Inc.
$28.61+$0.26 (+0.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $2.6B
- P/E
- -67.3x
- EV / EBITDA
- 58.9x
- Revenue
- $719.0M
- Net margin
- -5.4%
- ROCE
- -3.3%
Price chart
Technical chartScreen technicals →-36.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -30.6%
- 3M
- -39.7%
- 6M
- -41.2%
- 1Y
- -36.1%
- 5Y
- -14.5%
52-week range
Day change +$0.26 (+0.9%) from $28 to $29 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in SUPN, bought on each weekday since 2021.
News & filings
What Supernus Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 38.5 million US dollars in fiscal 2025.
Strengths (1)
- The company carries almost no debt: debt to equity of 0.04.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Read moreShow less
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
- Sector
- Healthcare
- Shares outstanding
- 57.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $2.6B
- P/E
- -67.3x
- P/B
- 2.4x
- EV / EBITDA
- 58.9x
- EV / Sales
- 3.5x
- P/S
- 3.6x
- 52-week high
- $56.32
- 52-week low
- $26.16
Profitability
- Operating margin
- -5.1%
- Net margin
- -5.4%
- EBITDA margin
- 5.9%
- ROE
- -3.6%
- ROCE
- -3.3%
- ROA
- -2.7%
- Asset turnover
- 0.49
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $719.0M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 8.6%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 2.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -152.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $46.0M
Solvency
- Current ratio
- 1.90
- Debt / Equity
- 0.04
- Debt / Assets
- 0.03
- CFO / Net profit
- -1.23
- Cash / Market cap
- 5.0%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $719.0M |
| Cost of revenue | $74.6M |
| Gross profit | $644.4M |
| Operating expenses | $681.3M |
| Research and development | $106.2M |
| Selling, general and administrative | $485.6M |
| Operating income | -$36.9M |
| Interest and other | -$12.2M |
| Pretax income | -$49.0M |
| Tax and other | -$10.5M |
| Net income | -$38.5M |
Revenue and net profit
Revenue grew 8.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $667.2M | $60.7M |
| FY2023 | $607.5M | $1.3M |
| FY2024 | $661.8M | $73.9M |
| FY2025 | $719.0M | -$38.5M |
Cash flows
FY2025: $47.3M from operations, $46.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $116.8M | $116.4M |
| FY2023 | $111.1M | $110.5M |
| FY2024 | $172.0M | $171.2M |
| FY2025 | $47.3M | $46.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $719.0M+8.6%1Y
- EBITDA
- $42.5M-76.1%1Y
- Net profit
- -$38.5M-152.2%1Y
- Cash from operations
- $47.3M-72.5%1Y
- Free cash flow
- $46.0M-73.1%1Y
- Revenue CAGR, 3Y
- 2.5%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $719.0M | $42.5M | -$38.5M | $46.0M | -3.6% | +8.6% | -152.2% |
Monthly returns
Month-by-month returns of SUPN across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.5B |
| Current assets | $644.2M |
| Non-current assets | $808.5M |
| Liabilities | $390.9M |
| Current liabilities | $338.2M |
| Non-current liabilities | $52.8M |
| Equity | $1.1B |
| Paid-in capital | $543.8M |
| Retained earnings | $517.9M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; SUPN highlighted.
P/E against peers
SUPN has no positive P/E; the peer median is 13.5x.
Not shown (no positive earnings and no EV / Sales): Supernus Pharmaceuticals, Inc., Arcus Biosciences, Inc., Acadia Healthcare Company, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc.SUPNthis company | $2.6B | -67.3x | 2.4x | -3.6% | 58.9x |
| Arcus Biosciences, Inc.RCUS | $3.1B | -8.8x | 4.9x | -55.9% | -8.9x |
| National HealthCare CorporationNHC | $2.9B | 24.5x | 2.7x | 11.2% | 13.7x |
| Privia Health Group, Inc.PRVA | $2.7B | 117.5x | 3.7x | 3.1% | 50.4x |
| TransMedics Group, Inc.TMDX | $2.5B | 13.0x | 5.2x | 40.2% | 16.8x |
| Acadia Healthcare Company, Inc.ACHC | $2.3B | -2.1x | 1.2x | -56.6% | -6.5x |
| Prestige Consumer Healthcare Inc.PBH | $2.2B | 11.3x | 1.1x | 10.1% | 9.5x |
| LeMaitre Vascular, Inc.LMAT | $2.1B | 37.0x | 5.4x | 14.7% | 25.3x |
| Select Medical Holdings CorporationSEM | $2.0B | 14.0x | 1.2x | 8.6% | 9.2x |
| Peer median | — | 13.5x | 3.2x | 9.3% | 11.6x |
Year-to-date ROI
SUPN since 1 January, against earlier years.
Historical volatility
SUPN's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 6.8% |
| FY2023 | 2.2% |
| FY2024 | 11.4% |
| FY2025 | -5.1% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $719.0M |
| Cost of revenueCost Of Revenue | $74.6M |
| Gross profitGross Profit | $644.4M |
| Operating expensesOperating Expense | $681.3M |
| Research and developmentResearch And Development | $106.2M |
| Selling, general and administrativeSelling General And Administration | $485.6M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $89.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $89.5M |
| Amortization | $89.5M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $89.5M |
| Total expensesTotal Expenses | $755.8M |
| Operating incomeOperating Income | -$36.9M |
| Interest and other | |
| Pretax incomePretax Income | -$49.0M |
| TaxTax Provision | -$10.5M |
| Net incomeNet Income | -$38.5M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.5B |
| Current assetsCurrent Assets | $644.2M |
| Non-current assetsTotal Non Current Assets | $808.5M |
| LiabilitiesTotal Liabilities Net Minority Interest | $390.9M |
| Current liabilitiesCurrent Liabilities | $338.2M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $52.8M |
| EquityTotal Equity Gross Minority Interest | $1.1B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $47.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $47.3M |
| Net income, continuing operationsNet Income From Continuing Operations | -$38.5M |
| Depreciation and amortisationDepreciation And Amortization | $91.6M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $91.6M |
| Amortization of securitiesAmortization Of Securities | -$1.5M |
| Stock-based compensationStock Based Compensation | $33.0M |
| Deferred taxDeferred Tax | $5.2M |
| Deferred income taxDeferred Income Tax | $5.2M |
| Operating gains and lossesOperating Gains Losses | $440.0k |
| Gain loss on investment securitiesGain Loss On Investment Securities | $440.0k |
| Asset impairmentAsset Impairment Charge | $1.9M |
| Change in working capitalChange In Working Capital | -$75.2M |
| Other non-cash itemsOther Non Cash Items | $30.4M |
| Investing cash flowInvesting Cash Flow | $4.1M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $4.1M |
| Capital expenditureCapital Expenditure | -$1.3M |
| Purchase of PP&EPurchase Of PPE | -$1.3M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$1.3M |
| AcquisitionsPurchase Of Business | -$293.1M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$293.1M |
| Purchase of investmentsPurchase Of Investment | -$475.9M |
| Sale of investmentsSale Of Investment | $774.5M |
| Net investment purchases and salesNet Investment Purchase And Sale | $298.5M |
| Dividends received (investing)Dividends Received Cfi | — |
| Financing cash flowFinancing Cash Flow | $9.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $9.1M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | $0.00 |
| Net debt issuedNet Issuance Payments Of Debt | $0.00 |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | $0.00 |
| Net long-term debt issuedNet Long Term Debt Issuance | $0.00 |
| Shares issuedIssuance Of Capital Stock | $37.6M |
| Common stock issuedCommon Stock Issuance | $37.6M |
| Net common stock issuedNet Common Stock Issuance | $37.6M |
| Other financing chargesNet Other Financing Charges | -$28.5M |
| Change in cashChanges In Cash | $60.6M |
| Cash at the start of the yearBeginning Cash Position | $69.3M |
| Cash at the end of the yearEnd Cash Position | $129.9M |
| Free cash flowFree Cash Flow | $46.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Supernus Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read